Medikra

Medikra Inc., an exempted company incorporated in the Cayman Islands, is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade botanical therapies. Through its wholly-owned Malaysian subsidiary, Medika Natura Sdn. Bhd., the company has established an integrated discovery and development platform that combines proprietary botanical extraction, preclinical and clinical trials, as well as multi-omics research. The company’s lead drug candidate, SKF7®, is in the development stage for the treatment of abdominal obesity and metabolic syndrome. Other programs include potential indications of SKF7® in neuroprotection, oncology, and other botanical candidates, which are currently in early or preclinical stages of development.